Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Key Points

• Immuneering will report Q1 2026 results before the market opens on Monday, May 4; analysts expect ($0.30) EPS, versus the prior quarter's ($0.18) EPS that beat estimates.
• Shares opened at $6.04 and trade within a 52-week range of $1.10–$10.08, with a market capitalization of about $390.8 million and a negative P/E of -4.38.
• Institutional investors own roughly 67.65% of the stock, and analysts have a consensus Moderate Buy rating with a consensus price target of $16.50, though individual ratings vary from Strong Buy to Sell.

Immuneering (NASDAQ:IMRX - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.13. On average, analysts expect Immuneering to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $6.04 on Monday. Immuneering has a 52-week low of $1.10 and a 52-week high of $10.08. The company has a 50 day moving average of $5.29 and a two-hundred day moving average of $5.75. The company has a market capitalization of $390.79 million, a price-to-earnings ratio of -4.38 and a beta of 0.43.

Institutional Trading of Immuneering

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company's stock worth $16,907,000 after buying an additional 1,358,322 shares in the last quarter. State Street Corp grew its position in shares of Immuneering by 1,289.7% during the fourth quarter. State Street Corp now owns 2,402,238 shares of the company's stock worth $15,807,000 after buying an additional 2,229,374 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Immuneering by 10.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company's stock worth $13,121,000 after buying an additional 195,176 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Immuneering during the third quarter worth approximately $6,602,000. Finally, Marshall Wace LLP grew its position in shares of Immuneering by 162.4% during the fourth quarter. Marshall Wace LLP now owns 711,875 shares of the company's stock worth $4,684,000 after buying an additional 440,571 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company's stock.

Analyst Ratings Changes

IMRX has been the subject of several recent research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research report on Monday, March 9th. Wall Street Zen raised shares of Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday, April 19th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immuneering has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.

About Immuneering

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.